Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of the median overall survival (OS). An exploratory analysis of entrectinib in ROS1 fusion-positive NSCLC with the central nervous system (CNS)-only progression post-crizotinib is reported.
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC / A. Drilon, C. Chiu, Y. Fan, B.C. Cho, S. Lu, M. Ahn, M.G. Krebs, S.V. Liu, T. John, G.A. Otterson, D.S.W. Tan, T. Patil, R. Dziadziuszko, E. Massarelli, T. Seto, R.C. Doebele, B. Pitcher, N. Kurtsikidze, S. Heinzmann, S. Siena. - In: JTO CLINICAL AND RESEARCH REPORTS. - ISSN 2666-3643. - 3:6(2022), pp. 100332.1-100332.13. [10.1016/j.jtocrr.2022.100332]
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC
S. Siena
Ultimo
2022
Abstract
Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of the median overall survival (OS). An exploratory analysis of entrectinib in ROS1 fusion-positive NSCLC with the central nervous system (CNS)-only progression post-crizotinib is reported.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2022 Drilon A et al JTO CRR.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
379.3 kB
Formato
Adobe PDF
|
379.3 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
